Value Dossier Icon

Further specifications on the GKV-FinStG law

In their 2nd and 3rd reading, the German Parliament has decided further specifications of the new law on the financial stabilisation of the statutory health insurances (GKV-FinStG). As already outlined in the draft of the law, the outcome of the AMNOG benefit assessment will further gain importance for the subsequent price negotiations. In case the

Pharmabarometer Update

Have a look at our latest update of German price negotiations for drugs that went through the AMNOG benefit assessment. The mean price decrease after negotiations was 28 % for all analysed products, 23 % for orphan drugs and 30 % for non-orphan drugs. If you have any further questions or suggestions, please feel free

2022-08-23T09:27:36+02:0023. August 2022|Reimbursement|0 Comments

GKV-FinStG cabinet decision: Power shift in favor of the statutory health insurance companies expected

The German cabinet, the coalition group of ministers,  has decided to introduce the draft bill on the financial stabilization of the statutory health insurance (GKV-FinStG) into the parliamentary process [GKV-Finanzstabilisierungsgesetz - Bundesgesundheitsministerium]. The subjects of the draft bill are amendments to the Social Code Book V, in particular sections § 35a and § 130b, which

GKV-FinStG draft law: The status of the comparator will impact the outcome of price negotiations

Recently, the German Federal Ministry of Health has published a draft law on the financial stabilization of the statutory health insurance (GKV-FinStG). In the following figure, we have summarized the newly proposed negotiation terms. The draft law intends for a stricter regulation of price negotiations following benefit assessments depending on the status of the most

GKV-FinStG draft law: Power shift in favor of the statutory health insurance companies expected

The German Federal Ministry of Health has published a draft law on the financial stabilization of the statutory health insurance (GKV-FinStG). The subjects of the draft are amendments to the Social Code Book V, in particular Articles § 35 a and § 130 b, which include the early benefit assessment of new active substances and

Go to Top